← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Neuromyelitis Optica

MONDO:0019100 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 23 citations asta · 20 citations perplexity · 52 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

NMOSD is fundamentally a primary autoimmune astrocytopathy in which astrocytes — bearing aquaporin-4 (AQP4) water channels concentrated on their perivascular end-foot processes — are the primary targets of autoimmune attack, with demyelination and neuronal injury occurring secondarily.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% NMOSD is a primary autoimmune astrocytopathy driven in most patients by pathogenic IgG1 autoantibodies against the water channel aquaporin-4 (AQP4) concentrated on astrocyte endfeet
Falcon states the astrocytopathy framing and the AQP4/end-foot localization directly.
DOI:10.1186/s41232-023-00291-5, DOI:10.1007/s00415-023-11910-z
asta CONCORDANT 90% Neuromyelitis optica (NMO) is a primary astrocytic disease associated with inflammation and secondary myelin loss in the central nervous system (CNS).
Asta's retrieved iPSC-astrocyte paper calls NMO a primary astrocytic disease with secondary myelin loss, matching the astrocytopathy framing.
PMID:34460995
perplexity CONCORDANT 97% a disease in which astrocytes are the primary targets of autoimmune destruction
Perplexity explicitly frames NMOSD as an astrocytopathy with astrocytes as primary targets.

AQP4-IgG binding to astrocytic AQP4 activates the classical complement pathway, progressing from C1q through C3 and C5 to formation of the C5b-9 membrane attack complex (MAC) that lyses astrocytes; complement-dependent cytotoxicity is the principal effector of astrocyte destruction.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 93% Binding of AQP4-IgG to AQP4 orthogonal arrays of particles on astrocytes activates the classical complement pathway, culminating in C5b-9 membrane attack complex (MAC)
Falcon describes the classical complement cascade culminating in the MAC.
DOI:10.1186/s41232-023-00291-5
asta CONCORDANT 90% The binding of AQP4-IgG onto the AQP4 extracellular epitopes initiates astrocyte damage through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Thus, a membrane attack complex is formed due to complement cascade activation; the membrane attack complex targets the AQP4 channels in the astrocytes, leading to astrocyte cell damage, demyelination of neurons and oligodendrocytes, and neuroinflammation.
Asta's retrieved review lays out CDC/ADCC and MAC-mediated astrocyte damage.
DOI:10.3390/app13085029
perplexity CONCORDANT 97% The complement cascade activated by AQP4-IgG follows the classical pathway, progressing from C1q engagement through the sequential activation of C1r, C1s, C4, and C2, continuing through amplification steps involving C3 and C5, and culminating in formation of the membrane attack complex (MAC or C5b-9).
Perplexity gives the full step-by-step classical pathway to MAC formation.

AQP4-IgG serostatus is the defining biomarker of NMOSD, with the large majority of patients (roughly 70-90%) testing seropositive for AQP4-IgG.

UNANIMOUS INTEGRATED
diagnosisepidemiology
ProviderStanceScoreEvidence
asta CONCORDANT 85% Approximately 70% to 80% of individuals with NMOSD exhibit positive results for AQP4-IgG antibody testing.
Asta cites a 70-80% AQP4-IgG seropositivity figure.
PMID:40489809
perplexity CONCORDANT 85% More than 80% of patients with NMOSD harbor circulating immunoglobulin G autoantibodies against AQP4
Perplexity puts seropositivity at more than 80%, slightly higher than Asta's band but within the same range.
falcon SILENT —
Falcon emphasizes the AQP4-IgG-positive form throughout but does not report a quantitative seroprevalence figure.

Complement-derived anaphylatoxin C5a recruits and activates neutrophils (polymorphonuclear leukocytes), whose proteases drive blood-brain barrier breakdown and amplify lesion expansion; C5a-receptor blockade reduces astrocyte loss in experimental models.

MAJORITY INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 92% C5a-driven recruitment/activation of neutrophils; neutrophil proteases and MMPs disrupt BBB; C5aR blockade reduces lesion burden
Falcon links C5a-driven neutrophil recruitment and proteases to BBB disruption and lesion burden.
DOI:10.1172/jci141694
perplexity CONCORDANT 93% complement-derived anaphylatoxins C3a and C5a function as potent chemoattractants, with C5a in particular inducing expression of adhesion molecules on brain endothelial cells and promoting trans-endothelial migration of circulating neutrophils into the CNS parenchyma.
Perplexity details C5a-driven neutrophil trans-endothelial migration and a dedicated PMN/BBB section.
asta PARTIAL 45% including inflammatory responses, amplification of immune responses, antibody-dependent cellular cytotoxicity, disruption of aquaporin function, early granulocyte recruitment, and complement-dependent cytotoxicity
Asta's retrieved text lists early granulocyte recruitment among disease mechanisms but does not tie C5a and neutrophil proteases specifically to BBB breakdown.

An IL-6/Th17 axis is central to NMOSD: IL-6 drives Th17 polarization and plasmablast survival while suppressing regulatory T cells, and both IL-6 and Th17-derived IL-17 increase blood-brain barrier permeability, facilitating entry of pathogenic antibodies and immune cells into the CNS.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 88% IL-6/Th17-axis signaling is integrally linked: ex vivo, AQP4-IgG/AQP4 immune complexes together with complement elicit IL-6 and IL-17A release from patient PBMCs
Falcon documents complement-dependent IL-6/IL-17A induction and Th17 biasing.
DOI:10.1038/s41598-024-53661-5
asta CONCORDANT 90% IL-6 induces T-cell polarization toward an inflammatory Th17 phenotype, inhibits T regulatory cell development, promotes B-cell differentiation into plasmablasts, and contributes to impaired integrity of the blood-brain barrier, thus enabling pathogenic antibodies and proinflammatory cells to enter the CNS.
Asta's retrieved satralizumab paper spells out the full IL-6/Th17/plasmablast/BBB axis.
PMID:40743487
perplexity CONCORDANT 90% IL-6 additionally promotes differentiation of naive T cells into pathogenic Th17 cells through activation of STAT3, and Th17 cells produce IL-17 which itself disrupts endothelial tight junctions and promotes transendothelial migration of neutrophils and eosinophils.
Perplexity describes IL-6-driven Th17 differentiation and IL-17-mediated tight-junction disruption.

Gut microbiota may prime NMOSD peripherally through molecular mimicry, with AQP4-specific T cells cross-reacting with homologous peptides in Clostridium perfringens, supporting a gut-brain axis in disease initiation.

MAJORITY LEAD
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Peripheral priming may involve gut microbiota molecular mimicry: AQP4-specific T cells cross-react with homologous peptides from Clostridium perfringens, supporting a gut-brain axis in NMOSD
Falcon asserts the C. perfringens molecular-mimicry gut-brain hypothesis.
DOI:10.3390/ijms25063179
asta CONCORDANT 90% T cells recognizing the AQP4 epitope showed cross-reactivity with homologous peptide sequences in C. perfringens proteins, suggesting that the gut microbiota plays an integral role in the pathogenicity of NMOSD.
Asta retrieves the same Yao gut-microbiota review with the C. perfringens cross-reactivity claim.
PMID:38542152
perplexity PARTIAL 50% The mechanism may involve T cell and B cell responses initially directed against pathogen-derived epitopes that cross-react with AQP4 sequences, a process known as molecular mimicry
Perplexity invokes molecular mimicry with pathogens (EBV, M. paratuberculosis, H. pylori) and diet-driven microbiota effects, but does not name the C. perfringens gut cross-reactivity specifically.

Mechanism-targeted biologics — terminal complement C5 inhibitors (eculizumab, ravulizumab), IL-6 receptor blockade (satralizumab, tocilizumab), and B-cell depletion (inebilizumab/anti-CD19, rituximab/ anti-CD20) — markedly reduce relapse rates in AQP4-IgG-positive NMOSD.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 93% Approved targeted therapies derive directly from mechanistic pathways: complement C5 inhibitors (eculizumab, ravulizumab), anti-CD19 B-cell depletion (inebilizumab), and IL-6 receptor blockade (satralizumab) reduce relapses in AQP4-IgG+ NMOSD
Falcon enumerates the three approved mechanism-based drug classes and their relapse benefit.
DOI:10.1007/s00415-023-11910-z
asta CONCORDANT 92% Phase 3 studies have shown significant relapse reduction compared to placebo, in patients treated with monoclonal antibodies against the interleukin-6 receptor ([IL-6R]; satralizumab) [19,20], against CD 19 present on CD19-expressing B cells (inebilizumab) [21], and against the C5 fraction of complement (eculizumab) [13].
Asta's retrieved review reports the pivotal phase-3 relapse reductions for the same three targets.
PMID:34530847
perplexity CONCORDANT 90% Complement inhibitors including eculizumab (terminal C5 complement inhibitor) have proven highly effective, with clinical trials demonstrating 94% relative risk reduction in relapse rates
Perplexity quantifies the C5-inhibitor effect and elsewhere covers IL-6 and B-cell depleting therapies with relapse-reduction figures.

NMOSD follows a relapsing course in which neurological disability accumulates in a stepwise, largely irreversible fashion at the time of clinical attacks, with little change between relapses — distinguishing it from the progressive course of multiple sclerosis.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
asta CONCORDANT 92% clinical deterioration in NMOSD patients is irreversible and almost exclusively takes place at the timing of clinical attacks with stepwise accumulation of neurological disability
Asta's retrieved Akaishi study directly states the stepwise, attack-linked, irreversible disability pattern.
PMID:32807848
perplexity CONCORDANT 92% In NMOSD, neurological disability accumulates almost exclusively at the time of clinical attacks through stepwise acquisition of fixed deficits from each demyelinating episode, with minimal spontaneous improvement or deterioration occurring between relapses.
Perplexity gives a dedicated disease-course section with the same stepwise attack-linked disability model.
falcon SILENT —
Falcon's pathophysiology-focused report notes secondary tissue loss but does not characterize the relapse pattern or disability-accumulation dynamics.

The clinical phenotype of NMOSD maps to AQP4-rich CNS regions, producing severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome (intractable nausea/vomiting/hiccups), with hypothalamic and brainstem involvement.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Clinical phenotypes tightly map to astrocyte-rich regions: severe optic neuritis, longitudinally extensive transverse myelitis (central cord gray), area postrema syndrome (intractable vomiting/hiccups), and hypothalamic lesions
Falcon ties the core phenotypes to astrocyte-rich anatomical regions.
DOI:10.1007/s00415-023-11910-z
asta CONCORDANT 85% The hallmark clinical manifestations of NMOSD are optic neuritis, resulting in vision loss, and longitudinally extensive transverse myelitis resulting in weakness, sensory impairment, and bladder and bowel dysfunction.
Asta's retrieved paper names optic neuritis and LETM as the hallmark manifestations.
PMID:40743487
perplexity CONCORDANT 93% The clinical phenotype of NMOSD results directly from the selective vulnerability of specific CNS regions to AQP4-IgG-mediated autoimmunity, particularly areas of highest AQP4 expression.
Perplexity dedicates sections to optic neuritis, LETM, area postrema syndrome, and hypothalamic/brainstem involvement, all anchored to AQP4-rich regions.

Narrative

Overview

All three providers frame NMOSD as an antibody-mediated autoimmune astrocytopathy of the CNS in which IgG1 autoantibodies against the astrocytic water channel aquaporin-4 (AQP4) — concentrated on perivascular end-foot processes at the blood-brain barrier — are the pathogenic hallmark, with demyelination and neuronal/axonal injury occurring secondarily to astrocyte destruction. The three differ mainly in scope and format rather than in the core model: falcon (Edison) is a focused pathophysiology narrative centered on the AQP4-IgG/complement/C5a-neutrophil/IL-6-Th17 mechanistic cascade and the biologics derived from it; perplexity (sonar-deep-research) is the broadest, adding AQP4 orthogonal-array biology, HLA/environmental risk factors, distinct axonal-injury and microglia/eosinophil/B-cell arms, the MOGAD contrast, double-negative NMOSD, and detailed clinical/prognostic sections; asta is a retrieval-only stream of Semantic Scholar snippets (no synthesis stage) that nonetheless surfaces the same core mechanism plus disease-course and gut-microbiota evidence.

Agreement

The providers converge strongly on the central pathogenic chain: AQP4-IgG binding to astrocytic AQP4 activates the classical complement pathway (C1q -> C3 -> C5) culminating in the C5b-9 membrane attack complex and complement-dependent astrocyte lysis, with antibody-dependent cellular cytotoxicity contributing. They agree that complement-derived C5a recruits and activates neutrophils that disrupt the blood-brain barrier and expand lesions, and that an IL-6/Th17 axis amplifies disease and further compromises the BBB. They also agree that mechanism-targeted biologics — terminal C5 inhibition, IL-6 receptor blockade, and B-cell depletion — substantially reduce relapse rates in AQP4-IgG-positive disease. Where two or more providers speak to it, they concur that AQP4-IgG serostatus is the defining biomarker and that the clinical phenotype maps to AQP4-rich regions (optic nerve, spinal cord/LETM, area postrema, hypothalamus/brainstem).

Divergence

Divergence is a matter of coverage and emphasis, not conflict — no provider contradicts another. Falcon is silent on quantitative seroprevalence and on the relapse/disability-accumulation course, consistent with its mechanism-only scope. Asta, being retrieval-only, supplies the seroprevalence figure (70-80%) and the clearest statement of stepwise, attack-linked, irreversible disability, but it offers only fragmentary coverage of the C5a-neutrophil-BBB link (it lists "early granulocyte recruitment" without integrating it). Perplexity uniquely elaborates AQP4 M1/M23 OAP biology, HLA genetics and environmental/infectious triggers, the axonal microtubule-injury mechanism, microglial and eosinophil arms, MOGAD vs AQP4-NMOSD distinctions, and double-negative NMOSD; it treats the gut-brain axis only at the general molecular-mimicry level rather than naming the C. perfringens cross-reactivity that falcon and asta both cite.

Integration

The consensus mechanistic backbone should be promoted into the disorder YAML: AQP4-IgG astrocytopathy, classical-complement/MAC-mediated astrocyte lysis (with ADCC), C5a-driven neutrophil recruitment and BBB breakdown, the IL-6/Th17 amplification arm, AQP4-IgG as the defining diagnostic biomarker (~70-90% seropositive), the anatomically selective phenotype (severe optic neuritis, longitudinally extensive transverse myelitis, area postrema syndrome, hypothalamic/brainstem involvement), the stepwise irreversible attack-linked disability course, and the three mechanism-based biologic drug classes (C5 inhibitors, IL-6R blockade, anti-CD19/anti-CD20 B-cell depletion). These are multiply supported and each carries verified provider quotes plus citable literature to run through the main curation pipeline.

Not integrated (leads)

The gut-microbiota / Clostridium perfringens molecular-mimicry gut-brain hypothesis is retained as a research lead rather than promoted: it is a plausible peripheral-priming mechanism cited by falcon and asta from a single 2024 review, but it is preliminary, perplexity supports only the general molecular-mimicry concept, and it is not yet established causal biology. Similarly, perplexity's single-provider expansions (AQP4 OAP structural detail, HLA risk alleles, vitamin-D/smoking/dietary risk factors, the microtubule-stabilization axonal-injury target, and the MOGAD/double-negative NMOSD distinctions) are worth tracking but need independent verification before promotion.

Three-way comparison of falcon (Edison, pathophysiology-focused), asta (retrieval-only Semantic Scholar snippets, no synthesis stage), and perplexity (sonar-deep-research, comprehensive). The three converge strongly on the core AQP4-IgG astrocytopathy/complement-MAC mechanism, the C5a-neutrophil and IL-6/Th17 amplification arms, and the mechanism-based biologic therapies. No direct contradictions were found; divergence is coverage/emphasis: falcon is silent on seroprevalence and disability dynamics (pathophysiology scope); asta provides only retrieval snippets and covers the C5a/BBB-neutrophil mechanism and the C. perfringens gut-mimicry lead but not their integration; perplexity is broadest (AQP4 OAP biology, HLA genetics, eosinophils, MOGAD contrast, double-negative NMOSD, environmental risk factors) but addresses the gut-brain mimicry only at the general molecular-mimicry level rather than the specific C. perfringens cross-reactivity. best_matching_text values are verbatim excerpts; literature evidence snippets and ontology terms were intentionally left to the main curation pipeline.